Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

gainst products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products.  In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.  We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products.  Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates.  Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative.  Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. 

Contacts:

Onyx Pharmaceuticals, Inc.
Danielle Bertrand (media)
1-650-266-2114

Amgen
Ashleigh Koss, 1-805-313-6151 (media)
Arvind Sood, 1-805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20131107/LA12955LOGO)


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... VA (PRWEB) , ... August 27, 2015 , ... ... contractors solve complex business problems, is pleased to announce their ranking as one of ... annual ranking of the fastest-growing private companies across the nation. , “It is truly ...
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... SAN DIEGO , Aug. 27, 2015 ... second annual meeting of the Japan Society of HTLV-1, ... Science Institute Auditorium. The purpose of the Society is ... well as the development of medical technology and research ... health and welfare. "HUYA is proud to ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based ... the product choices to a manageable shortlist of bench and floor scales and ... that fit best with the customer’s industry and application. , Side-by-side product ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2
... ARIUS Research Inc., (TSX:,ARI), a biotechnology company discovering ... announced its financial and operational,results for the first ... "During the quarter, we continued to focus ... human clinical trials. Most,significantly, we completed our pre-IND ...
... In the event of an outbreak or a bioterrorist ... virulence or drug resistance is essential to mounting an ... a pathogen genome is time-intensive and likely impractical during ... comparative genomics strategy to drastically reduce the time needed ...
... for Use as Pharmacologic ... in Myocardial Perfusion Imaging-, PALO ALTO, Calif. and ... CVTX ) and Astellas Pharma US, Inc. today,announced ... approved,Lexiscan(TM) (regadenoson) injection, an A2A adenosine receptor agonist,for use ...
Cached Biology Technology:ARIUS announces first quarter fiscal 2008 financial results 2ARIUS announces first quarter fiscal 2008 financial results 3ARIUS announces first quarter fiscal 2008 financial results 4ARIUS announces first quarter fiscal 2008 financial results 5ARIUS announces first quarter fiscal 2008 financial results 6ARIUS announces first quarter fiscal 2008 financial results 7ARIUS announces first quarter fiscal 2008 financial results 8ARIUS announces first quarter fiscal 2008 financial results 9ARIUS announces first quarter fiscal 2008 financial results 10ARIUS announces first quarter fiscal 2008 financial results 11ARIUS announces first quarter fiscal 2008 financial results 12Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing 2CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection 2CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection 3CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection 4CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection 5
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/10/2015)... and TELTOW, Germany , ... Instruments (SMI), a world leader in Eye Tracking ... completion of its OEM Eye Tracking Platform for integration ... Tracking Platform contains reference designs for seamless integration of ... systems, virtual reality HMDs and augmented reality smart glasses. ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... event of an infection, the immune system releases messenger ... defeat invading pathogens, or inhibit them to prevent an ... to decide very quickly what mixture of activating and ... from the Helmholtz-Centre for Infection Research in Braunschweig, Germany, ...
... the Genome Institute of Singapore (GIS), a biomedical research ... (A*STAR), and their colleagues from the National University of ... Princeton University have recently discovered that viruses that ,invaded, ... the way genes get turned on and off in ...
... brain by the hunger-signaling hormone ghrelin, researchers say. The ... pharmacologic control of cholesterol levels. The animal ... University of Cincinnati (UC) endocrinology division, appears online ahead ... Neuroscience . "We have long thought that ...
Cached Biology News:The right response to every pathogen 2Scientists discover ancient viral invasion that shaped human genome 2Scientists discover ancient viral invasion that shaped human genome 3'Remote control' for cholesterol regulation discovered in brain 2
... Hitachi Innovative Linear Ion Trap Time of Flight Mass Analyzer for ... mode measurement range: 100 - 25,000 m/z, * Precursor ion selection ... over, * MS accuracy: 5 ppm with internal reference, * Dynamic ... ...
Four siRNAs targeting your gene of interest, providing gene silencing with 100% satisfaction guaranteed High knockdown potency , High specificity for minimal off-target effects , Flexible siR...
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
... series combines Harvard Apparatuss best pump mechanism, a ... range of configuration options. A lookup table in ... from all the major manufacturers. A bright, two ... information from across the lab. All models have ...
Biology Products: